Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 6:10:3305-3315.
doi: 10.2147/CMAR.S175703. eCollection 2018.

The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies

Chai Hong Rim  1 , Chul Yong Kim  2 , Dae Sik Yang  3 , Won Sup Yoon  1
Affiliations

The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies

Chai Hong Rim et al. Cancer Manag Res. .

Abstract

Purpose: Lymph node metastasis of hepatocellular carcinoma is categorized as advanced in Barcelona Clinic of Liver Cancer staging, and sorafenib is a sole treatment recommended. However, appliance of local treatment including external beam radiotherapy (EBRT) has not been uncommon. We performed a meta-analysis and systemically reviewed current literature to evaluate the efficacy and safety of EBRT.

Methods: PubMed, Medline, Cochrane library, and Embase were systemically searched until December 17, 2017. The primary endpoint of analyses was response rate (RR), and 1-year overall survival and complication rates of grade ≥3 were secondary endpoints. Complications were primarily assessed descriptively.

Results: A total of 8 studies comprising 521 patients were included. The pooled RR was 73.1% (95% confidence interval [CI]: 63.6-80.9), and high-dose EBRT groups had better RR than the low-dose group (82.2% [95% CI: 74.4-88.1] vs 51.1% [95% CI: 40.3-61.7]; P=0.001]. The pooled 1-year overall survival rate was 41.0% (95% CI: 32.9-49.6). Six studies assessed the survival benefit according to RR, and 5 (83.3%) of these 6 studies reported statistically significant survival benefit. The most common grade ≥3 toxicities were thrombocytopenia and gastrointestinal complication, with pooled rates of 3.4% (95% CI: 1.2-9.5) and 3.5% (95% CI:1.7-7.2), respectively.

Conclusion: EBRT showed a pooled RR of 73.1% and was safely performed. EBRT might palliate symptoms through tumor reductions and improve survival. Use of sorafenib combined or sequentially with EBRT can be recommended rather than monotherapy.

Keywords: hepatocellular carcinoma; lymph node metastasis; meta-analysis; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The study inclusion process.
Figure 2
Figure 2
(A) Forest plots of the RRs and 1-year OS rates. The P-values from the Cochran Q test and I2 statistics are described below the figures. Significant heterogeneity among the studies was found in regard to RRs, but not in 1-year OS rates. (B) Forest plots of RRs comparing high- and low-dose groups. The P-value was derived from a Q-test, based on an analysis of the variance and a random-effects model, where P (total between) <0.001 suggests a significant difference of RRs between high-dose and low-dose subgroups. Abbreviations: OS, overall survival; RR, response rate.
Figure 3
Figure 3
(A) Forest plot of GI toxicities of grade 3 or higher, (B) forest plot of thrombocytopenia of grade 3 or higher. Abbreviations: CI, confidence interval; GI, gastrointestinal.
Figure 4
Figure 4
Funnel plots assessing RRs and OS rates. Abbreviations: OS, overall survival; RR, response rate.
See this image and copyright information in PMC

References

    1. Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol. 2007;96(1):37–45. - PubMed
    1. Ercolani G, Grazi GL, Ravaioli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg. 2004;239(2):202–209. - PMC - PubMed
    1. Awazu M, Fukumoto T, Takebe A, et al. Lymphadenectomy combined with locoregional treatment for multiple advanced hepatocellular carcinoma with lymph node metastases. Kobe J Med Sci. 2013;59(1):E17–E27. - PubMed
    1. Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011;18(4):559–566. - PubMed
    1. Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698–703. - PubMed

LinkOut - more resources